Cadila Pharmaceuticals Sweden AB acquires BioChromix NewCo AB

PRESS RELEASE
Published: October 2, 2014
Cadila Pharmaceuticals Sweden AB acquires BioChromix NewCo AB
STOCKHOLM, SWEDEN - October 2, 2014. Cadila Pharmaceuticals Limited, one of India’s leading
research- driven pharmaceuticals companies, announced today the acquisition of BioChromix NewCo
AB, Sweden, through its subsidiary, Cadila Pharmaceuticals Sweden AB. The subsidiary had been
incorporated recently to explore and facilitate business interactions between Cadila Pharmaceuticals,
prospective collaborators and academic groups.
BioChromix NewCo AB develops new and innovative therapies targeting protein misfolding, which is
believed to be a key culprit in the development of certain neurodegenerative diseases.
BioChromix NewCo’s unique compound class is believed to selectively bind to, neutralize and
eliminate soluble, toxic protein oligomers, protofibrils and soluble aggregates that are thought to
contribute to the neurodegenerative process in many diseases affecting the nervous system.
Cadila Pharmaceuticals will continue the preclinical and clinical development of drug candidates that
have been developed by BioChromix NewCo. According to the agreement, the development will be
milestone based and will be conducted at Cadila Pharmaceuticals’ state-of-the-art research facility in
Ahmedabad, Gujarat, India. With all the necessary resources required, Cadila Pharmaceuticals Ltd.
will take this program into clinical development and further towards the market.
“This acquisition gives the opportunity to take the project, previously conducted by BioChromix
NewCo, forward with great resources. Cadila Pharmaceuticals’ drug development expertise matched
with BioChromix NewCo’s scientific excellence in its area provides a solid platform for the further
development of these novel drug candidates. If successfully developed, valuable deals could be
signed in major territories such as the US and Europe”, says Dr. Peter Åsberg (Former CEO of
BioChromix NewCo proposed change of name to CPL BCX PHARMA AB).
Speaking on the occasion, Dr Rajiv I. Modi, Chairman and Managing Director, Cadila Pharmaceuticals
said: “A lot of promising research work is being done across the world, especially Europe, which is
complementary to our drug discovery portfolio. The acquisition of BioChromix NewCo through our
Swedish subsidiary is a step towards developing indigenous novel solutions, at our world-class
facility, for the treatment of neurodegenerative diseases, a therapeutic segment which is of great
significance to us.”
“Going from discoveries of the interaction of electronic polymers with misfolded proteins in the
university laboratory to medical innovation is a long step. The intellectual capital vested in
BioChromix NewCo was created through transfer of university projects to the small development
companies BioChromix AB and BioChromix Pharma AB. With the present acquisition of BioChromix
NewCo by Cadila Pharmaceuticals, this knowledge is transferred to an organization capable of taking
these possibilities to the clinic. I hope that it ultimately leads to novel treatment that will slow down
disease progression and create a future benefit for patients suffering from these neurodegenerative
diseases”, says Olle Inganäs, co-founder of BioChromix NewCo and professor at Linköping University,
Sweden.
For further information, please contact:
Rajiv Modi, Chairman and Managing Director, Cadila Pharmaceuticals Ltd.
Phone: +91 (0)27 18 22 50 01, e-mail: [email protected]
Peter Åsberg (Former CEO, BioChromix NewCo AB
proposed change of name to CPL BCX PHARMA AB)
Phone: +46 (0)70 949 17 21, e-mail: [email protected]
TO THE EDITORS
About Cadila Pharmaceuticals (www.cadilapharma.com)
Cadila Pharmaceuticals is one of the largest privately held pharmaceuticals companies in India,
headquartered at Ahmedabad, Gujarat, India. Established in 1951, the company develops and
manufactures pharmaceutical products and sells and distributes these in all major markets across the
globe. It is an integrated healthcare solutions provider with a comprehensive therapeutic basket
including oncology, pulmonology, neurology and cardiovascular.
Cadila Pharmaceuticals is a research and innovation driven company and has collaborations with
premier academic and research-based organisations across the world.
Cadila Pharmaceuticals was the first Indian company to get IND approval by USFDA for clinical trials
to be conducted in India. Subsequently, the company has filed 5 INDs with the USFDA.
About BioChromix NewCo AB proposed change of name to CPL BCX PHARMA AB
(www.biochromix.com)
BioChromix NewCo AB develops new and innovative therapies targeting protein misfolding, which is
believed to be a key culprit in the development of certain neurodegenerative diseases.
BioChromix NewCo AB was founded in 2013 based on the idea that the technology developed by
BioChromix AB and BioChromix Pharma AB could be useful to treat patients suffering from
neurodegenerative diseases such as Alzheimer’s disease, Amyotrophic Lateral Sclerosis, Parkinson
Disease and other. All relevant IP rights on the unique class of conjugated heteocyclic compounds for
the treatment of protein misfolding disease were transferred to BioChromix NewCo AB during the
inception of the Company.

Download Report